Animals are infected by intranasal inoculation with RSV-A2. This is a non-lethal model that has been used to successfully test RSV vaccine and therapeutic candidates leading to IND and clinical development. Model kinetics indicate peak viral burden at day 4 or 5 post challenge followed by recovery through day7.